BioScrip Inc. (NASDAQ:BIOS) shares rose 2.9% during mid-day trading on Tuesday . The stock traded as high as $2.83 and last traded at $2.81, with a volume of 427,094 shares. The stock had previously closed at $2.73.

Separately, Zacks Investment Research upgraded shares of BioScrip from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a research note on Monday, July 11th.

The stock has a 50-day moving average of $2.64 and a 200 day moving average of $2.41. The stock’s market cap is $318.86 million.

BioScrip (NASDAQ:BIOS) last released its earnings results on Monday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by $0.05. The firm had revenue of $232.50 million for the quarter, compared to analysts’ expectations of $229.58 million. BioScrip’s revenue for the quarter was down 11.4% on a year-over-year basis. Analysts forecast that BioScrip Inc. will post ($0.27) EPS for the current year.

In related news, Director Coliseum Capital Management, L acquired 4,200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 22nd. The stock was bought at an average price of $2.00 per share, for a total transaction of $8,400,000.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director David W. Golding acquired 12,500 shares of the firm’s stock in a transaction that occurred on Friday, June 17th. The shares were bought at an average price of $2.48 per share, with a total value of $31,000.00. Following the acquisition, the director now directly owns 42,500 shares in the company, valued at $105,400. The disclosure for this purchase can be found here.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.